How A Pfizer Cancer Drug Pact Launched Celcuity Stock Into A Breakout

How A Pfizer Cancer Drug Pact Launched Celcuity Stock Into A Breakout

Celcuity broke out and soared to a nearly two-year high Friday after striking a licensing deal with Pfizer for a breast cancer treatment. Celcuity paid Pfizer $10 million in cash and stock.